PACB – Pacific Biosciences of California, Inc.
Pacific Biosciences of CalifornPACB
$2.19Name : Pacific Biosciences of Californ
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $679,165,184.00
EPSttm : -0.42
Pacific Biosciences of Californ
$2.19
2.46%$0.055
PACB — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
16.4
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
-0.02
EPS Last/This Y
1.3
EPS This/Next Y
0.1
Price
2.24
Target Price
2.74
Analyst Recom
2.25
Performance Q
101.8
Upside
-349.6%
Beta
2.21
Ticker: PACB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | PACB | 2.11 | 0.08 | 0.96 | 192779 |
| 2026-10-13 | PACB | 2.06 | 0.08 | 0.14 | 193861 |
| 2026-10-14 | PACB | 1.99 | 0.08 | 1.49 | 193667 |
| 2026-10-15 | PACB | 1.96 | 0.08 | 0.49 | 193294 |
| 2026-10-16 | PACB | 1.74 | 0.08 | 0.41 | 193059 |
| 2026-10-19 | PACB | 1.84 | 0.07 | 0.15 | 176152 |
| 2026-10-20 | PACB | 1.965 | 0.07 | 0.03 | 177367 |
| 2026-10-21 | PACB | 2.145 | 0.07 | 0.21 | 177806 |
| 2026-10-22 | PACB | 2.055 | 0.07 | 0.02 | 178229 |
| 2026-10-23 | PACB | 2.11 | 0.07 | 0.05 | 178190 |
| 2026-10-26 | PACB | 2.26 | 0.07 | 0.00 | 178323 |
| 2026-10-27 | PACB | 2.45 | 0.06 | 0.00 | 198467 |
| 2026-10-28 | PACB | 2.83 | 0.06 | 0.03 | 208632 |
| 2026-10-29 | PACB | 2.9 | 0.06 | 0.03 | 224414 |
| 2026-10-30 | PACB | 2.61 | 0.06 | 2.92 | 229329 |
| 2026-11-02 | PACB | 2.35 | 0.08 | 0.12 | 233975 |
| 2026-11-03 | PACB | 2.44 | 0.08 | 0.27 | 234210 |
| 2026-11-04 | PACB | 2.57 | 0.08 | 0.16 | 234639 |
| 2026-11-05 | PACB | 2.42 | 0.08 | 0.03 | 235051 |
| 2026-11-06 | PACB | 2.26 | 0.08 | 0.29 | 238186 |
| 2026-11-09 | PACB | 2.36 | 0.08 | 3.04 | 238112 |
| 2026-11-10 | PACB | 2.25 | 0.08 | 9.71 | 239174 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | PACB | 2.11 | -9.2 | - | -0.52 |
| 2026-10-13 | PACB | 2.04 | -9.2 | - | -0.52 |
| 2026-10-14 | PACB | 1.99 | -9.2 | - | -0.52 |
| 2026-10-15 | PACB | 1.97 | -9.2 | - | -0.52 |
| 2026-10-16 | PACB | 1.74 | -9.2 | - | -0.52 |
| 2026-10-19 | PACB | 1.84 | -9.2 | - | -0.52 |
| 2026-10-20 | PACB | 1.84 | -9.2 | - | -0.52 |
| 2026-10-21 | PACB | 1.97 | -9.2 | - | -0.52 |
| 2026-10-22 | PACB | 2.05 | -9.2 | - | -0.52 |
| 2026-10-23 | PACB | 2.11 | -9.2 | - | -0.52 |
| 2026-10-26 | PACB | 2.26 | -9.2 | - | -0.52 |
| 2026-10-27 | PACB | 2.45 | -9.2 | - | -0.52 |
| 2026-10-28 | PACB | 2.82 | -9.2 | - | -0.52 |
| 2026-10-29 | PACB | 2.91 | -9.2 | - | -0.52 |
| 2026-10-30 | PACB | 2.61 | -9.2 | - | -0.52 |
| 2026-11-02 | PACB | 2.34 | -9.2 | - | -0.52 |
| 2026-11-04 | PACB | 2.57 | -9.2 | - | -0.52 |
| 2026-11-05 | PACB | 2.41 | -9.2 | - | -0.52 |
| 2026-11-06 | PACB | 2.25 | -9.2 | - | -0.52 |
| 2026-11-09 | PACB | 2.37 | -9.2 | - | -0.52 |
| 2026-11-10 | PACB | 2.24 | -9.2 | - | -0.52 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | PACB | -2.61 | 1.13 | 16.56 |
| 2026-10-13 | PACB | -2.61 | 1.13 | 16.56 |
| 2026-10-14 | PACB | -2.61 | 1.13 | 16.56 |
| 2026-10-15 | PACB | -2.52 | 1.13 | 16.62 |
| 2026-10-16 | PACB | -2.52 | 1.13 | 16.62 |
| 2026-10-19 | PACB | -2.52 | 1.16 | 16.62 |
| 2026-10-20 | PACB | -2.52 | 1.16 | 16.62 |
| 2026-10-21 | PACB | -2.52 | 1.16 | 16.62 |
| 2026-10-22 | PACB | -2.52 | 1.16 | 16.62 |
| 2026-10-23 | PACB | -2.52 | 1.16 | 16.62 |
| 2026-10-26 | PACB | -2.52 | 1.08 | 16.62 |
| 2026-10-27 | PACB | -2.52 | 1.08 | 16.51 |
| 2026-10-28 | PACB | -2.52 | 1.08 | 16.51 |
| 2026-10-29 | PACB | -2.52 | 1.08 | 16.51 |
| 2026-10-30 | PACB | -2.52 | 1.08 | 16.51 |
| 2026-11-02 | PACB | -2.52 | 1.10 | 16.51 |
| 2026-11-03 | PACB | -2.52 | 1.10 | 16.51 |
| 2026-11-05 | PACB | -2.52 | 1.10 | 16.51 |
| 2026-11-06 | PACB | -2.52 | 1.10 | 16.51 |
| 2026-11-09 | PACB | -2.51 | 1.06 | 16.40 |
| 2026-11-10 | PACB | -2.51 | 1.06 | 16.40 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.11
Avg. EPS Est. Current Quarter
-0.13
Avg. EPS Est. Next Quarter
-0.13
Insider Transactions
-2.51
Institutional Transactions
1.06
Beta
2.21
Average Sales Estimate Current Quarter
39
Average Sales Estimate Next Quarter
43
Fair Value
Quality Score
30
Growth Score
37
Sentiment Score
24
Actual DrawDown %
92.3
Max Drawdown 5-Year %
-96.9
Target Price
2.74
P/E
Forward P/E
PEG
P/S
4.34
P/B
P/Free Cash Flow
EPS
-0.43
Average EPS Est. Cur. Y
-0.52
EPS Next Y. (Est.)
-0.42
Target Price Estimates Raised
2
Target Price Estimates Lowered
Profit Margin
-81.31
Relative Volume
0.7
Return on Equity vs Sector %
187.5
Return on Equity vs Industry %
202.9
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
PACB
Healthcare
$2.24
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
49.8
Range 1M
39.2%
Sup Dist
1.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
75.7%
EPS NY
2.3%
52W%
49.3%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+22.3% upside
Upside
+22.3%
Quality
30
PACB — P/E HistoricalDiagnostics & Research
Pacific Biosciences of CalifornSector: Healthcare
Industry: Medical Devices
Employees: 485
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
PACB
Latest News
—
Caricamento notizie per PACB…
stock quote shares PACB – Pacific Biosciences of California, Inc. Stock Price stock today
news today PACB – Pacific Biosciences of California, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PACB – Pacific Biosciences of California, Inc. yahoo finance google finance
stock history PACB – Pacific Biosciences of California, Inc. invest stock market
stock prices PACB premarket after hours
ticker PACB fair value insiders trading